Expanded Insurance for Weight-Loss Medications Propels Eli Lilly to a Trillion-Dollar Valuation

2026-05-31 companies

New York, Sunday, 31 May 2026.
CVS Health’s late May 2026 decision to restore coverage for Eli Lilly’s obesity medications has driven the pharmaceutical giant’s market valuation back into the exclusive $1 trillion club.

A Monumental Market Reversal

On May 27, 2026, CVS Health (NYSE: CVS) announced a significant policy reversal, revealing that its pharmacy benefit manager, CVS Caremark, would reinstate coverage for Eli Lilly’s blockbuster weight-loss injection, Zepbound [5][6]. The financial markets responded swiftly. Shares of Eli Lilly (NYSE: LLY) surged by 4.1% to reach an all-time closing high of $1,126.80, successfully vaulting the pharmaceutical company’s market capitalization back over the $1 trillion threshold—a milestone it first crossed in November 2025 [1]. Conversely, shares of rival Novo Nordisk fell by up to 2.4% in Copenhagen following the announcement [6].

The Economics of Access and Affordability

The financial friction surrounding GLP-1 therapies has been a defining narrative in healthcare economics. In mid-2025, CVS Caremark controversially excluded Zepbound from its covered medications list, favoring Novo Nordisk’s Wegovy due to cost concerns [3][7]. The exclusion was highly disruptive, prompting a class-action lawsuit and leading Eli Lilly to transition its own 50,000 employees away from Caremark to a competing provider, Riteway, in November 2025 [4][6]. With Zepbound carrying a staggering U.S. list price of over $1,000 per month, the financial toll on the system has been immense [6]. By 2026, the average healthcare costs for a family of four reached $37,824, driven in part by a nearly 15% surge in pharmacy expenses heavily attributed to GLP-1 and specialty drugs [5].

Competitive Dynamics and the Shift to Oral Therapies

The battle for dominance in the obesity treatment sector is fiercely contested between Eli Lilly and Novo Nordisk. Currently, Eli Lilly commands approximately 60% of the combined diabetes and obesity market, fortified by Zepbound’s impressive 2025 sales of $13.5 billion [6]. The competition is now expanding from injectable treatments to daily pills. Following the FDA approval of Novo Nordisk’s oral Wegovy in December 2025, Eli Lilly launched its own weight-loss pill, Foundayo, in April 2026 [4]. Analysts at Citi anticipate that the addition of Foundayo to CVS Caremark’s commercial template will significantly bolster the drug’s early launch momentum [4].

Future Implications for Employer Health Plans

The integration of high-cost obesity medications into standard health plans represents a pivotal shift in employer-sponsored healthcare. According to Mercer, 49% of large employers covered GLP-1 medications in 2025, up from 41% in 2023 [5]—representing an impressive 19.512% relative increase in adoption over that two-year span. Concurrently, the Kaiser Family Foundation reported a 43% coverage rate among employers [5]. The reinstatement of Zepbound and the rapid inclusion of Foundayo by the nation’s largest pharmacy benefit manager will likely pressure remaining holdouts to expand their coverage options [GPT].

Sources

Eli Lilly Zepbound